Purchase by Waksal Harlan of 25000 shares of Lyra TherapeuticsInc

LYRA Stock  USD 0.19  0.01  5.56%   
About 71 percent of all Lyra Therapeutics' investors are curious in acquiring. The analysis of the overall investor sentiment regarding Lyra Therapeutics suggests that a large number of traders are confidant. The current market sentiment, together with Lyra Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lyra Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Lyra Therapeutics Inc director. General open market or private purchase of non-derivative or derivative security

Read at macroaxis.com
Lyra insider trading alert for perchase of common stock by Waksal Harlan, Executive Chair, on 13th of November 2023. This event was filed by Lyra Therapeutics Inc with SEC on 2023-11-13. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Lyra Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Lyra Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Lyra Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Lyra Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Lyra Therapeutics Fundamental Analysis

We analyze Lyra Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lyra Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lyra Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Outstanding

Shares Outstanding Comparative Analysis

Lyra Therapeutics is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Lyra Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lyra Therapeutics stock to make a market-neutral strategy. Peer analysis of Lyra Therapeutics could also be used in its relative valuation, which is a method of valuing Lyra Therapeutics by comparing valuation metrics with similar companies.

Peers

Lyra Therapeutics Related Equities

CTMXCytomX Therapeutics   7.87   
0%
100.0%
BOLTBolt Biotherapeutics   3.45   
0%
43.0%
NUVBNuvation Bio   3.21   
0%
40.0%
CGEMCullinan Oncology   2.62   
0%
33.0%
AUTLAutolus Therapeutics   1.36   
0%
17.0%
ACHLAchilles Therapeutics   0.94   
0%
11.0%
NXTCNextCure   0.84   
0%
10.0%
TILInstil Bio   0.08   
0%
1.0%
SPROSpero Therapeutics   0.86   
10.0%
0%
ASMBAssembly Biosciences   1.53   
19.0%
0%
DAWNDay One   2.19   
27.0%
0%

Complementary Tools for Lyra Stock analysis

When running Lyra Therapeutics' price analysis, check to measure Lyra Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lyra Therapeutics is operating at the current time. Most of Lyra Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lyra Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lyra Therapeutics' price. Additionally, you may evaluate how the addition of Lyra Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Fundamental Analysis
View fundamental data based on most recent published financial statements
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
CEOs Directory
Screen CEOs from public companies around the world